Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.51 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | KCNJ1 | P48048 | 3/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5964092 | 0.85 | CNR2 (0.42) | CNR2KDM4ESMN1; SMN2MEN1KMT2A | |
| SCHEMBL5964014 | 0.84 | CNR2 (0.73) | CNR2KDM4ESMN1; SMN2MEN1KMT2A | |
| SCHEMBL5964322 | 0.83 | CNR2 (0.68) | CNR2AOC3KDM4ESMN1; SMN2MEN1 | |
| SCHEMBL6192020 | 0.81 | CNR2 (0.59) | CNR2AOC3KDM4ESMN1; SMN2MEN1 | |
| SCHEMBL5964140 | 0.81 | CNR2 (0.59) | CNR2AOC3KDM4ESMN1; SMN2MEN1 | |
| SCHEMBL5964624 | 0.81 | CNR2 (0.46) | CNR2KDM4ESMN1; SMN2MEN1KMT2A | |
| SCHEMBL5963820 | 0.78 | CNR2 (0.72) | CNR2AOC3KDM4ESMN1; SMN2MEN1 | |
| SCHEMBL5963797 | 0.77 | CNR2 (0.53) | CNR2AOC3KDM4ESMN1; SMN2MEN1 | |
| SCHEMBL28339068 | 0.76 | AOC3 (0.62) | CNR2AOC3KDM4ESMN1; SMN2MEN1 | |
| SCHEMBL5964087 | 0.74 | MAOB (0.48) | MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060052315-A1 | Cb 1/cb 2 receptor ligands and their use in the treatment of pain | ASTRAZENECA AB (SE) | 2006-03-09 | — | — | US | claimed |
| EP-1594856-A1 | CB 1/CB 2 RECEPTOR LIGANDS AND THEIR USE IN THE TREATMENT OF PAIN | AstraZeneca AB (SE) | 2005-11-16 | — | — | EP | claimed |
| WO-2004060882-A1 | CB 1/CB 2 RECEPTOR LIGANDS AND THEIR USE IN THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2004-07-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052315-A1 | Cb 1/cb 2 receptor ligands and their use in the treatment of pain | CNR1, CNR2, OPRL1 | CNR2 2/4885AOC3 1673/4885KDM4E 3936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.